Is pneumonectomy still necessary?

Perentes, Jean Yannis; Zellweger, Matthieu; Gonzalez, Michel

doi:10.21037/jtd.2018.11.18

Cited by 9 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have read with great interest the letter from Dr. Perentes and colleagues (1) with his comments about our recent paper (2). Dr. Perentes agrees with our results affirming that for the treatment of centrally located lung cancer sleeve lobectomy should be preferred over pneumonectomy even after induction treatment.…”

supporting

confidence: 78%

Pushing the limits in order to avoid pneumonectomy

Maurizi¹,

Vanni²,

Rendina³

2019

J. Thorac. Dis.

View full text Add to dashboard Cite

supporting

confidence: 78%

Pushing the limits in order to avoid pneumonectomy

Maurizi¹,

Vanni²,

Rendina³

2019

J. Thorac. Dis.

View full text Add to dashboard Cite

“…Several studies or meta-analyses have demonstrated better post-operative outcomes and better quality of life in favor of pulmonary sleeve resection in comparison with pneumonectomy, with equivalent oncological outcomes (3)(4)(5)(6). However, SL has been associated with higher distant recurrence rates than pneumonectomy in disease with nodal involvement (N1 or N2) (7,8). Thereby, induction treatment by either chemotherapy and/or radiotherapy is currently used to reduce the size of the tumor to potentially avoid the pneumonectomy and facilitate parenchymasparing procedures.…”

Section: Original Articlementioning

confidence: 99%

Is sleeve lobectomy safe after induction therapy?—a systematic review and meta-analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Sleeve lobectomy (SL) is a lung-sparing procedure, which is accepted as a valid operation for centrally-located advanced tumors. These tumors often require induction treatment by chemotherapy and/ or radiotherapy to downstage the disease and thus facilitate subsequent surgery. However, induction therapy may potentially increase the risk of bronchial anastomotic complications and related morbidity. This metaanalysis aims to determine the impact of induction therapy on the outcomes of pulmonary SL. Methods: We compared studies of patients undergoing SL or bilobectomy for non-small cell lung cancer (NSCLC) with and without induction therapy. Outcomes of interest were in-hospital mortality, morbidity, anastomosis complication and 5-year survival. Odds ratio (OR) were computed following the Mantel-Haenszel method. Results: Ten studies were included for a total of 1,204 patients. There was no statistical difference for between patients who underwent induction therapy followed by surgery and patients who underwent surgery alone in term of post-operative mortality (OR: 1.80, 95% confidence interval (CI): 0.76-4.25, P value =0.19) and morbidity (OR: 1.17, 95% CI: 0.90-1.52, P value =0.237). Anastomosis related complications rate were 5.2% and appears increased after induction therapy with a statistical difference close to the significance (OR:1.65, 95% CI: 0.97-2.83, P value =0.06). Patients undergoing surgery alone showed better survival at 5 years (OR: 1.52, 95% CI: 1.15-2.00, P value =0.003).Conclusions: SL following induction therapy can be safely performed with no increase of mortality and morbidity. However, the need for induction therapy before surgery is associated with increased anastomotic complications and poorer survival prognosis at 5 years.

show abstract

“…When assessing outcomes among operative techniques, other prognostic factors may play a substantial role in the resulting mortality rates. Patients who undergo pneumonectomies have involvement of different lobes or centralized bronchovascular structures, meaning their disease is more extensive than those who undergo lobectomies (24). However, several studies have reported more favorable post-operative mortality rates following pneumectomies, including a single-institution study with a rate of 6.8% and a review of the STS-GTSD with a rate of 5.6% (25,26).…”

Section: Benefits Of Surgerymentioning

confidence: 99%

Management of stage IIIA non-small-cell lung cancer: role of surgery

Iranpour¹,

Olive²,

Antonoff³

2021

Curr Chall Thorac Surg

View full text Add to dashboard Cite

The present role of surgery Controversy has long surrounded the indication of surgical resection as a treatment modality for stage IIIA non-small cell lung cancer (NSCLC). Stage IIIA disease tends to be neither as clearly resectable as earlier stages of NSCLC, nor has it reached the point of distant metastasis in which resection has historically been rarely considered (1). As defined by the American Joint Committee on Cancer (AJCC) TNM staging system, IIIA NSCLC includes T3N1M0, T4N0M0, T4N1M0, T1N2M0, and T2N2M0 disease (1). The variability in treatment decision-making may result from the inclusion of a vastly heterogenous population of disease. Management of N2 disease, which is defined as ipsilateral mediastinal nodal involvement,

show abstract

Is pneumonectomy still necessary?

Cited by 9 publications

References 25 publications

Pushing the limits in order to avoid pneumonectomy

Pushing the limits in order to avoid pneumonectomy

Is sleeve lobectomy safe after induction therapy?—a systematic review and meta-analysis

Management of stage IIIA non-small-cell lung cancer: role of surgery

Contact Info

Product

Resources

About